Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Updates FY 2026 Earnings Guidance

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) updated its FY 2026 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 1.251-1.400 for the period. The company issued revenue guidance of $52.4 billion-$54.7 billion, compared to the consensus revenue estimate of $53.9 billion.

Analysts Set New Price Targets

BAYRY has been the topic of a number of recent research reports. Barclays upgraded Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research report on Tuesday, January 6th. JPMorgan Chase & Co. raised Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a research report on Monday, December 8th. Zacks Research lowered Bayer Aktiengesellschaft from a “strong-buy” rating to a “hold” rating in a report on Monday, February 23rd. Morgan Stanley raised shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research note on Wednesday, December 3rd. Finally, DZ Bank cut shares of Bayer Aktiengesellschaft from a “strong-buy” rating to a “strong sell” rating in a research report on Wednesday, February 18th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy”.

Bayer Aktiengesellschaft Stock Performance

BAYRY opened at $11.01 on Thursday. The company has a quick ratio of 0.71, a current ratio of 1.14 and a debt-to-equity ratio of 1.10. The company has a market cap of $43.27 billion, a price-to-earnings ratio of -122.32, a PEG ratio of 4.34 and a beta of 0.69. Bayer Aktiengesellschaft has a 52-week low of $5.30 and a 52-week high of $14.85. The firm’s fifty day simple moving average is $12.43 and its two-hundred day simple moving average is $9.87.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last released its earnings results on Wednesday, March 4th. The company reported $0.18 EPS for the quarter, hitting analysts’ consensus estimates of $0.18. Bayer Aktiengesellschaft had a negative net margin of 0.68% and a positive return on equity of 16.46%. The business had revenue of $13.24 billion during the quarter, compared to analysts’ expectations of $13.08 billion. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.251-1.400 EPS. Equities analysts anticipate that Bayer Aktiengesellschaft will post 1.31 earnings per share for the current fiscal year.

Key Headlines Impacting Bayer Aktiengesellschaft

Here are the key news stories impacting Bayer Aktiengesellschaft this week:

• Positive Sentiment: Initial court sign-off on a proposed $7.25 billion Roundup settlement reduces a major legal overhang and the uncertainty around future jury awards, which investors view as lowering tail risk for Bayer. Bayer’s $7.25 billion Roundup settlement gets initial OK from Missouri judge
• Positive Sentiment: Analysts and screens point to BAYRY as a value opportunity given depressed share price, steady cash generation and restructuring progress — a supporting narrative for longer-term investors. Here’s Why Bayer Aktiengesellschaft (BAYRY) is a Strong Value Stock
• Neutral Sentiment: Bayer updated FY2026 guidance to EPS €1.251–1.400 and revenue €52.4–€54.7B (roughly in line with consensus), signalling management expects stability and modest growth but not a material beat. (Guidance file provided by company announcement)
• Neutral Sentiment: Management described Q4 as “solid execution” operationally but emphasized the remaining legal overhang — useful context but stops short of reversing investor caution. Bayer Earnings Call: Solid Execution, Heavy Legal Overhang
• Neutral Sentiment: Full Q4 2025 earnings call transcript available for detail review (useful for investors digging into segment-level commentary). Bayer Aktiengesellschaft (BAYRY) Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Company reiterates expectation of stable 2026 profit but flags that glyphosate/glyphosat uncertainty remains a risk to outcomes. ROUNDUP 2: Bayer erwartet 2026 stabilen Gewinn – Glyphosat-Unsicherheit bleibt
• Negative Sentiment: Bayer reported a wider net loss driven by a €3.55 billion litigation-related hit, underscoring that legal costs are still materially weighing on earnings and headline profitability. Bayer Net Loss Widens on Weedkiller Litigation Charges
• Negative Sentiment: Operational results showed another multi-billion euro loss overall despite some better-than-expected operational metrics — reinforces the view that headline earnings remain volatile while litigation is resolved. Bayer mit weiterem Milliardenverlust – Operativ etwas besser als gedacht
• Negative Sentiment: Q4 revenue missed expectations as sales of Xarelto and Eylea declined, highlighting near-term top-line pressure in key pharma products. Bayer Q4 Earnings Match Estimates, Xarelto and Eylea Pull Down Sales

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.